Glyphic Biotechnologies
Building a next-generation proteomics platform enabling single-molecule protein sequencing with single amino acid resolution at proteome-wide scale.
Notes
Glyphic Biotechnologies is developing a next-generation proteomics platform capable of sequencing proteins at single amino acid resolution across thousands to millions of peptides. The company's technology aims to achieve full proteome coverage, enabling deeper insights into protein biology than current mass spectrometry approaches.
The company's platform uses a proprietary single-molecule protein sequencing approach that could revolutionize proteomics research, drug discovery, and diagnostics by providing more comprehensive protein analysis than existing technologies.
Glyphic emerged from research at Yale University and has attracted significant venture investment to advance its technology platform.
Team
- Joshua Schoen, Ph.D. - Co-founder & CEO
- LinkedIn: linkedin.com/in/joshuaschoen
- David Rimm, M.D., Ph.D. - Scientific Co-founder (Yale Professor)
- Team with expertise in proteomics, biochemistry, and instrument development
Additional Research Findings
- Founded in 2019, based in Boston
- Spun out from Yale University research
- Single-molecule protein sequencing technology
- Full proteome coverage capability
- Raised significant Series A funding
- Backed by top life science investors
- Competing with Quantum-Si, Nautilus, and others
- Applications in drug discovery, diagnostics, and research
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |